MPNRF | May 25, 2023
While the Annual Meeting of the American Association for Cancer Research (AACR), held in April 2023, focused a great deal on understanding, decoding, and advocating for cancer health equity and inclusion, there were also significant scientific take-aways important to the treatment of MPNs.
One presentation by Haris Ali, MD, City of Hope Comprehensive Cancer Center, showed that once-weekly selinexor administered at 60 mg in combination with ruxolitinib (Jakafi) achieved rapid, deep, sustained spleen responses and robust symptom improvements in patients with treatment-naïve myelofibrosis. This according to a phase 1/2 study.
Other important MPN presentations included:
- • Efficacy of Jak1/2 inhibition in murine MPN mediated by targeting nonmalignant cells (Sivahari Prasad, PhD )
- • Preclinical characterization of the BET inhibitor, INCB057643, in combination with ruxolitinib for treatment of MPN (Gaurang Trivedi, Ph.D.)
- • Preclinical efficacy of CDK7 inhibitor-based combinations in cellular models of advanced MPN (Christopher Mill, Ph.D.)